KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Other Accumulated Expenses (2020 - 2025)

Gilead Sciences (GILD) has disclosed Other Accumulated Expenses for 11 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 27.65% year-over-year to $4.0 billion, compared with a TTM value of $4.0 billion through Dec 2025, down 27.65%, and an annual FY2025 reading of $4.0 billion, down 27.65% over the prior year.
  • Other Accumulated Expenses was $4.0 billion for Q4 2025 at Gilead Sciences, up from $3.8 billion in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $6.1 billion in Q4 2021 and bottomed at $3.6 billion in Q2 2025.
  • Average Other Accumulated Expenses over 5 years is $4.8 billion, with a median of $4.6 billion recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses surged 168.69% in 2021, then dropped 27.65% in 2025.
  • Year by year, Other Accumulated Expenses stood at $6.1 billion in 2021, then fell by 25.47% to $4.6 billion in 2022, then increased by 12.01% to $5.1 billion in 2023, then grew by 6.51% to $5.5 billion in 2024, then dropped by 27.65% to $4.0 billion in 2025.
  • Business Quant data shows Other Accumulated Expenses for GILD at $4.0 billion in Q4 2025, $3.8 billion in Q3 2025, and $3.6 billion in Q2 2025.